Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Pneumatic Tube System Versus Personnel Transport and the Hemolysis Index of Emergency Department Blood Samples: A Randomized, Split-Sample, Single-Blind Trial (PTS-HEMO-ED)

18 septembre 2026 mis à jour par: Emir Ünal, Marmara University Pendik Training and Research Hospital

Hemolysis is the most common pre-analytical error in emergency department (ED) laboratory specimens and can lead to false elevation of intracellular analytes (potassium, LDH, AST, hemoglobin), resulting in misdiagnosis and unnecessary testing. Blood samples in the ED are transported to the laboratory either by pneumatic tube systems (PTS) or manually by personnel. Although PTS shortens turnaround time, the forces generated during transport may damage erythrocyte membranes and promote hemolysis. Evidence on whether PTS increases hemolysis compared with personnel transport is inconsistent, partly because existing studies use parallel-group designs that cannot control for between-subject biological variability, and partly because findings differ across PTS brands and configurations. The Sumetzberger Power Control PTS installed at Marmara University Pendik Training and Research Hospital (speed 4-5 m/s, 120 m, cushioned capsule) has not been prospectively validated for hemolysis risk. This study uses a randomized, split-sample (within-patient matched), single-blind design in which two simultaneously drawn yellow-cap tubes from the same patient are randomly allocated, one to PTS and one to personnel transport, thereby eliminating between-patient variability. The primary outcome is the Hemolysis Index (HI) category (ordinal scale 0-5 corresponding to free hemoglobin thresholds of <50, 50-99, 100-199, 200-299, 300-500, and >500 mg/dL). Secondary outcomes include the rate of clinically significant hemolysis (HI >= 1 / free Hb >= 50 mg/dL) and the correlation between transport time and HI.

Aperçu de l'étude

Description détaillée

PNEUMATIC TUBE SYSTEM TECHNICAL SPECIFICATIONS

The installed pneumatic tube system is a Sumetzberger Power Control system (Sumetzberger, Austria). The transit line length between the Emergency Department phlebotomy station and the central clinical laboratory is approximately 120 meters. System operating speed is set at 4-5 m/s. Transport capsules are cushioned with internal foam padding to minimize mechanical impact forces. Average transit duration ranges between 50 and 90 seconds.

BLOOD COLLECTION PROTOCOL

Blood collection is performed by trained emergency department phlebotomists using standard venipuncture technique. Tubes are drawn from a single venipuncture in the standard order of draw: (1) blue-cap coagulation tube, not used in the study; (2) yellow-cap serum separator tube #1; (3) yellow-cap serum separator tube #2; (4-5) any additional clinically indicated tubes, not used in the study. The two yellow-cap serum separator tubes are dispatched simultaneously by the two transport routes and are analysed simultaneously on arrival at the laboratory, so that waiting time does not act as a pre-analytical variable.

RANDOMIZATION AND ALLOCATION CONCEALMENT (CONSORT 2025 Items 15-17)

Allocation is by computer-generated block randomization with a block size of four. The allocation sequence assigns each participant to Sequence A (tube #1 to the pneumatic tube system, tube #2 to personnel transport) or Sequence B (tube #1 to personnel transport, tube #2 to the pneumatic tube system). The sequence is held in sealed, opaque, sequentially numbered envelopes that are opened in order at the time of enrolment. This scheme balances any effect of tube draw order across the two transport routes.

BLINDING (CONSORT 2025 Item 12b)

Tubes are labeled with standardized participant study identifiers and tube sequence numbers (Tube #1 and Tube #2) without indicating transport allocation. Laboratory technicians operating the automated analyzer and assessing the Hemolysis Index remain fully blinded to transport allocation. Clinicians and investigators are not blinded.

WITHDRAWAL CRITERIA

A participant's tube pair is withdrawn from analysis if pneumatic transport cannot be completed because of system failure, if a tube is broken or otherwise cannot be analyzed, or if the participant withdraws consent.

HARMS (CONSORT 2025 Item 27)

No intervention is applied to the participant. Both tubes are drawn from the venipuncture already required for routine clinical care, and no additional venipuncture or other invasive procedure is performed. No participant-level adverse events are therefore anticipated and no harms outcome measure is specified.

PATIENT AND PUBLIC INVOLVEMENT (PPI) STATEMENT (CONSORT 2025 Item 8)

Patients or members of the public were not involved in the design, conduct, reporting, or dissemination plans of this research. PPI was deemed non-applicable given the technical, pre-analytical nature of this laboratory quality evaluation study.

DATA SHARING STATEMENT (CONSORT 2025 Item 4)

De-identified individual participant data collected during the trial will be made available upon reasonable request to the corresponding investigator following publication.

Type d'étude

Interventionnel

Inscription (Estimé)

166

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

  • Nom: Emir Ünal, Assistant Professor
  • Numéro de téléphone: +905327766010
  • E-mail: emirunal@gmail.com

Sauvegarde des contacts de l'étude

Lieux d'étude

    • Pendik
      • Istanbul, Pendik, Turquie (Türkiye), 34899
        • Recrutement
        • Marmara University Pendik Training and Research Hospital
        • Contact:

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • Adults aged 18 years or older
  • Presenting to the emergency department of Marmara University Pendik Training and Research Hospital
  • Venous blood draw required for routine clinical care, allowing two yellow-cap (serum separator) tubes to be drawn from the same venipuncture
  • Written informed consent provided by the participant or, where the acute clinical condition of the participant prevents this, by a legal representative

Exclusion Criteria:

  • Known underlying hemolytic disorder (e.g., hemolytic anemia, sickle cell disease, G6PD deficiency, autoimmune hemolytic anemia, or TTP/HUS)
  • Macroscopic hemolysis visible in the sample tube immediately after phlebotomy
  • Age younger than 18 years

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Autre
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation croisée
  • Masquage: Seul

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Autre: PTS-First Sequence

Participants from whom two yellow-cap serum separator blood tubes are drawn simultaneously. Tube #1 (first drawn) is transported via the pneumatic tube system (PTS), and Tube #2 (second drawn) is transported by manual personnel. Both tubes are dispatched simultaneously.

Blood sample transport using the Sumetzberger Power Control pneumatic tube system (Sumetzberger, Austria). The system operates at a speed of 4-5 m/s over a distance of approximately 120 meters using cushioned capsules. Transport duration ranges between 50 and 90 seconds.

Blood sample transport performed manually by emergency department staff carrying the tube on foot from the phlebotomy area to the central clinical laboratory. Transport is dispatched simultaneously with the paired pneumatic tube sample.

Autre: Personnel-First Sequence

Participants from whom two yellow-cap serum separator blood tubes are drawn simultaneously. Tube #1 (first drawn) is transported by manual personnel, and Tube #2 (second drawn) is transported via the pneumatic tube system (PTS). Both tubes are dispatched simultaneously.

Blood sample transport using the Sumetzberger Power Control pneumatic tube system (Sumetzberger, Austria). The system operates at a speed of 4-5 m/s over a distance of approximately 120 meters using cushioned capsules. Transport duration ranges between 50 and 90 seconds.

Blood sample transport performed manually by emergency department staff carrying the tube on foot from the phlebotomy area to the central clinical laboratory. Transport is dispatched simultaneously with the paired pneumatic tube sample.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Hemolysis Index (HI) Category in PTS-Transported vs. Personnel-Transported Tubes
Délai: At laboratory analysis (within 30 minutes of blood draw)

Ordinal 6-category HI scale (0=<50, 1=50-99, 2=100-199, 3=200-299, 4=300-500, 5=>500 mg/dL free hemoglobin) as reported by the automated analyser. Higher category indicates more hemolysis. Compared between PTS and personnel tube from the same patient (paired).

At laboratory analysis (within 30 minutes of blood draw)

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Rate of Clinically Significant Hemolysis (HI ≥ 1) in PTS-Transported vs. Personnel-Transported Tubes
Délai: At laboratory analysis (within 30 minutes of blood draw)

Proportion of tubes with HI category ≥ 1 (free haemoglobin ≥ 50 mg/dL), the threshold at which samples are typically flagged for rejection by the laboratory. Dichotomous outcome (0 vs ≥1) compared between matched tube pairs.

At laboratory analysis (within 30 minutes of blood draw)

Autres mesures de résultats

Mesure des résultats
Description de la mesure
Délai
Spearman Correlation Between Tube Transport Time and HI Category
Délai: At laboratory analysis (within 30 minutes of blood draw)

Spearman rank correlation coefficient (ρ) between recorded PTS transport time (seconds, 50-90 s range) and the HI category of the PTS tube. Exploratory analysis.

At laboratory analysis (within 30 minutes of blood draw)

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Les enquêteurs

  • Chercheur principal: Emir Ünal, Marmara University

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

1 septembre 2026

Achèvement primaire (Estimé)

1 novembre 2026

Achèvement de l'étude (Estimé)

1 janvier 2027

Dates d'inscription aux études

Première soumission

5 août 2026

Première soumission répondant aux critères de contrôle qualité

5 août 2026

Première publication (Réel)

10 août 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

23 septembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

18 septembre 2026

Dernière vérification

1 septembre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

OUI

Description du régime IPD

De-identified individual participant data collected during the trial that underlie the published results will be made available upon reasonable request to qualified scientific researchers.

Délai de partage IPD

Data will become available beginning 3 months following publication and ending 36 months following article publication.

Critères d'accès au partage IPD

Proposals should be submitted to the corresponding investigator via email (emirunal@gmail.com). Requestors must provide a methodologically sound research proposal and sign a data use agreement.

Type d'informations de prise en charge du partage d'IPD

  • PROTOCOLE D'ÉTUDE
  • SÈVE

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner